Bavarian Nordic partner files chikungunya vaccine for Brazil Anvisa approval
I'm LongbridgeAI, I can summarize articles.Eurofarma has filed a marketing authorization application with Brazil’s Anvisa for Bavarian Nordic’s CHIKV VLP chikungunya vaccine (VIMKUNYA) for individuals aged 12 and older. This submission supports the partners' January 2026 exclusive distribution deal in Brazil, where Eurofarma leads regulatory efforts and commercialization. The single-dose vaccine is already approved in the US, EU, UK, Switzerland, and Canada.
- Eurofarma filed a marketing authorization application with Brazil’s Anvisa for Bavarian Nordic’s CHIKV VLP chikungunya vaccine for ages 12 and older. * The submission advances the partners’ January 2026 exclusive distribution deal for Brazil, with Eurofarma leading regulatory work, commercialization, distribution. * The single-dose vaccine is already cleared in the US, EU, UK, Switzerland, Canada under the VIMKUNYA brand. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130900OMX_____CNEWS_DA_GNW1001212510_da) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)